Comparative Pharmacology
Head-to-head clinical analysis: IOMERVU versus IOPAMIDOL 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOMERVU versus IOPAMIDOL 250.
IOMERVU vs IOPAMIDOL-250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays by increasing radiopacity of blood vessels and tissues, allowing visualization during imaging procedures.
Iopamidol is a non-ionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. It acts by increasing the radiodensity of blood vessels and organs.
Intravenous: 0.5-2 mL/kg of iomeprol 300-400 mg I/mL for imaging, not exceeding 200 mL total dose; arterial: up to 250 mL per procedure.
1-2 mL/kg intravenously for contrast imaging, not to exceed 200 mL total; dose and rate vary by procedure and patient weight.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In renal impairment, half-life is prolonged (up to 10-30 hours in severe impairment), necessitating dose adjustment and monitoring. The half-life is not significantly affected by hepatic impairment.
Terminal half-life 1.5-2 hours in normal renal function; may extend to 5-10 hours in severe renal impairment (CrCl <30 mL/min)
Iomeprol is almost exclusively eliminated via renal glomerular filtration, with 92-98% of the administered dose recovered unchanged in urine within 24 hours. Less than 2% is excreted in feces via biliary elimination. In patients with normal renal function, renal clearance approximates glomerular filtration rate.
Renal: >90% unchanged via glomerular filtration; biliary/fecal: <2%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent